What's new — Generalized anxiety disorder¶
Generated 2026-11-01 from the publication dates of every paper cited in this condition's pages.
This page answers a different question from the curation log. The log says when we last edited a page; this says how recent the evidence on those pages is — so you can tell settled ground from a field that is actively moving, and jump straight to what has emerged lately.
How much of this condition's evidence is recent¶
| Published within | Cited papers |
|---|---|
| last week | 0 |
| last month | 3 |
| last 2 months | 11 |
| last 3 months | 11 |
| last 6 months | 14 |
| last year | 26 |
| older than a year | 379 |
Counts are cumulative: a paper from last week also counts inside "last month". Dates are PubMed publication or e-publication dates, so a paper may have appeared online before its journal issue.
Newest evidence first¶
The most recent cited papers, with the pages that use them.
| Published | Paper | Cited on |
|---|---|---|
| 2026-10-08 | Time to generalized anxiety disorder onset after substance use disorder: a survival analysis from a national sample — Psychiatry Res ([PMID 42868720](https://pubmed.ncbi.nlm.nih.gov/42868720/){target="_blank" rel="noopener"}) | comorbidity-and-primary-care |
| 2026-10-08 | DT120 (MM120): a single-dose orally disintegrating formulation of lysergide tartrate for generalized anxiety disorder — Expert Rev Neurother ([PMID 42848417](https://pubmed.ncbi.nlm.nih.gov/42848417/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-10-02 | Psychiatric, Sociodemographic, and Community Belonging Correlates of Suicidal Ideation in Canada: Findings from the 2022 Mental Health and Access to Care Survey — Can J Psychiatry ([PMID 42924883](https://pubmed.ncbi.nlm.nih.gov/42924883/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-10-01 | Age-stratified signals and early onset of adverse events with pregabalin: a disproportionality analysis of the FDA adverse event reporting system — Front Med (Lausanne) ([PMID 42889226](https://pubmed.ncbi.nlm.nih.gov/42889226/){target="_blank" rel="noopener"}) | red-flags-and-safety-concerns |
| 2026-10-01 | Estimates of Anxiety Symptoms Among US Adolescents — JAMA Pediatr ([PMID 42862569](https://pubmed.ncbi.nlm.nih.gov/42862569/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-10-01 | Reconsidering the health-related burden of mental and physical disorders in the presence of comorbidity: evidence from China Mental Health Survey — Epidemiol Psychiatr Sci ([PMID 42858455](https://pubmed.ncbi.nlm.nih.gov/42858455/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-09-03 | PrEgabalin for Treatment Resistant generalised Anxiety disorder (PETRA): study protocol for a double-blind randomised controlled trial set in the UK — Trials ([PMID 42717383](https://pubmed.ncbi.nlm.nih.gov/42717383/){target="_blank" rel="noopener"}) | clinical-trials-landscape, pregabalin-benzodiazepines-and-others, treatment-resistant-gad |
| 2026-09-02 | The 39 symptoms of generalized anxiety disorder: Limited overlap among seven common GAD scales — J Anxiety Disord ([PMID 42809893](https://pubmed.ncbi.nlm.nih.gov/42809893/){target="_blank" rel="noopener"}) | screening-and-measurement |
| 2026-09-02 | Irritability and Emotion Dysregulation Predict Escitalopram Response in Adolescents with Generalized Anxiety Disorder: A Secondary Analysis of a Randomized, Double-Blind, Placebo-Controlled Trial — J Child Adolesc Psychopharmacol ([PMID 42773855](https://pubmed.ncbi.nlm.nih.gov/42773855/){target="_blank" rel="noopener"}) | special-populations |
| 2026-09-01 | Efficacy of prescription-eligible digital health applications for depression and generalized anxiety disorder in Germany: a systematic review and meta-analysis — Sci Rep ([PMID 42728340](https://pubmed.ncbi.nlm.nih.gov/42728340/){target="_blank" rel="noopener"}) | digital-and-remote-delivery |
| 2026-09-01 | Prevalence of Generalized Anxiety Disorder in Psychiatric Outpatients (PRADO Study): A Multicenter Cross-Sectional Study in Japan — Neuropsychiatr Dis Treat ([PMID 42701687](https://pubmed.ncbi.nlm.nih.gov/42701687/){target="_blank" rel="noopener"}) | epidemiology-and-burden |
| 2026-06-05 | Self-Guided Internet-Based Mindfulness-Informed Stress Management for Generalized Anxiety Disorder: Randomized Controlled Trial With Longitudinal Network Analysis — J Med Internet Res ([PMID 42247657](https://pubmed.ncbi.nlm.nih.gov/42247657/){target="_blank" rel="noopener"}) | digital-and-remote-delivery |
| 2026-06-02 | Genome-wide genetic overlap between fear-based disorders and generalised anxiety disorder — Mol Psychiatry ([PMID 42374129](https://pubmed.ncbi.nlm.nih.gov/42374129/){target="_blank" rel="noopener"}) | mechanism-and-models, the-diagnostic-boundary |
| 2026-06-01 | Risk of all-cause and cause-specific mortality, and suicide attempt in people with anxiety and stress-related disorders: a systematic review, meta-analysis and meta-regression analysis of 165 studies — World Psychiatry ([PMID 42136520](https://pubmed.ncbi.nlm.nih.gov/42136520/){target="_blank" rel="noopener"}) | course-relapse-and-long-term-outcome, overview |
| 2026-05-01 | Longitudinal Association Between Generalized Anxiety Disorder and Cognitive Change: A Meta-Analysis — Psychiatry Investig ([PMID 42191132](https://pubmed.ncbi.nlm.nih.gov/42191132/){target="_blank" rel="noopener"}) | course-relapse-and-long-term-outcome, mechanism-and-models |
| 2026-04-02 | Developing a core outcome set for generalized anxiety disorder during the perinatal period: Identifying core treatment outcomes in perinatal anxiety — Br J Clin Psychol ([PMID 42003419](https://pubmed.ncbi.nlm.nih.gov/42003419/){target="_blank" rel="noopener"}) | clinical-trials-landscape |
| 2026-02-03 | Genome-wide association study of major anxiety disorders in 122,341 European-ancestry cases identifies 58 loci and highlights GABAergic signaling — Nat Genet ([PMID 41634414](https://pubmed.ncbi.nlm.nih.gov/41634414/){target="_blank" rel="noopener"}) | clinical-trials-landscape, mechanism-and-models, the-diagnostic-boundary |
| 2026-02-02 | Effects of MBSR and escitalopram on self-compassion in anxiety disorders — J Psychiatr Res ([PMID 41759355](https://pubmed.ncbi.nlm.nih.gov/41759355/){target="_blank" rel="noopener"}) | other-psychological-therapies |
| 2026-01-27 | Therapeutic Use of Cannabis and Cannabinoids: A Review — JAMA ([PMID 41296368](https://pubmed.ncbi.nlm.nih.gov/41296368/){target="_blank" rel="noopener"}) | pregabalin-benzodiazepines-and-others |
| 2026-01-02 | Remote Measurement-Based Care Interventions for Mental Health: Systematic Review and Meta-Analysis — JMIR Ment Health ([PMID 41603797](https://pubmed.ncbi.nlm.nih.gov/41603797/){target="_blank" rel="noopener"}) | screening-and-measurement |
| 2026-01-02 | Participant Experience in a Study of Dietary Counselling plus Omega-3 Supplementation for the Treatment of Generalized Anxiety Disorder among Women: A Focus Group Study — Neuropsychobiology ([PMID 41587136](https://pubmed.ncbi.nlm.nih.gov/41587136/){target="_blank" rel="noopener"}) | patient-experience-and-advocacy |
| 2026-01-01 | Uptake, Adherence, and Attrition in Clinical Trials of Depression and Anxiety Apps: A Systematic Review and Meta-Analysis — JAMA Psychiatry ([PMID 41259035](https://pubmed.ncbi.nlm.nih.gov/41259035/){target="_blank" rel="noopener"}) | digital-and-remote-delivery |
| 2025-12-01 | Generative AI Mental Health Chatbots as Therapeutic Tools: Systematic Review and Meta-Analysis of Their Role in Reducing Mental Health Issues — J Med Internet Res ([PMID 41401240](https://pubmed.ncbi.nlm.nih.gov/41401240/){target="_blank" rel="noopener"}) | digital-and-remote-delivery |
| 2025-12-01 | Digital Cognitive Behavioral Treatment for Generalized Anxiety Disorder: A Randomized Clinical Trial — JAMA Netw Open ([PMID 41396602](https://pubmed.ncbi.nlm.nih.gov/41396602/){target="_blank" rel="noopener"}) | digital-and-remote-delivery |
| 2025-11-02 | Efficacy of standalone smartphone apps for mental health: an updated systematic review and meta-analysis — Lancet Digit Health ([PMID 41290454](https://pubmed.ncbi.nlm.nih.gov/41290454/){target="_blank" rel="noopener"}) | digital-and-remote-delivery |
| 2025-11-01 | Efficacy of acupuncture versus sham acupuncture on generalized anxiety disorder: a meta-analysis of randomized controlled trials — Front Neurol ([PMID 41312341](https://pubmed.ncbi.nlm.nih.gov/41312341/){target="_blank" rel="noopener"}) | other-psychological-therapies |
Trials — what has moved¶
45 registered trials are cited by this condition's pages. Registry records were re-checked live when this page was generated, so status, enrolment and results-posting below reflect ClinicalTrials.gov as of that date.
| Registry activity | Trials |
|---|---|
| trial records updated in the last week | 1 |
| trial records updated in the last month | 6 |
| trial records updated in the last 2 months | 14 |
| trial records updated in the last 3 months | 17 |
| trial records updated in the last 6 months | 20 |
| trial records updated in the last year | 23 |
Recently updated registrations¶
Posted efficacy and safety results¶
Trials whose sponsors have posted results to the registry. Adverse-event figures are participant counts summed across all arms as reported — read them against enrolment, and follow the registry link for the arm-by-arm breakdown that determines whether a signal is real.
| Results posted | Trial | Phase | N | Primary outcome | Serious AE | Other AE | Deaths |
|---|---|---|---|---|---|---|---|
| 2025-03-20 | A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of An | PHASE2 | 198 | Dose Response | 1 | 167 | 0 |
| 2022-12-28 | Randomized Trial of Adult Participants With Generalized Anxiety Disord | PHASE3 | 881 | Change From Baseline in the HAM-A Total Score at Week 8 | 4 | 137 | 0 |
| 2022-11-14 | A Study of Escitalopram in the Treatment of Children and Adolescents W | PHASE4 | 273 | Change in Pediatric Anxiety Rating Scale (PARS) Severity Score | 3 | 71 | 0 |
| 2019-12-18 | Safety, Efficacy and Tolerability of Vilazodone in (GAD) Generalized A | PHASE3 | 415 | Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) | 3 | 196 | 0 |
| 2019-12-18 | Safety, Efficacy and Tolerability of Vilazodone in Patients With Gener | PHASE3 | 402 | Change in Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) To | 0 | 205 | 0 |
| 2019-12-18 | Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety | PHASE3 | 680 | Change From Baseline in the Hamilton Rating Scale for Anxiety (HAM-A) | 2 | 329 | 0 |
| 2018-09-26 | EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder ( | PHASE3 | 495 | Change From Baseline in Hamilton Anxiety Rating Scale (HAM-A) Total Sc | 2 | 195 | 0 |
| 2017-04-25 | Child and Adolescent Anxiety Disorders (CAMS) | PHASE3 | 488 | Clinical Global Impression - Improvement Scale | 3 | 0 | 0 |
26 of these trials are still recruiting or active — see the condition's clinical trials page for the full landscape.
Which pages rest on the newest evidence¶
🔥 marks a page citing three or more papers from the last year — the pages worth re-reading if you have been away.
| Page | Newest citation | In last year | Total citations |
|---|---|---|---|
| clinical-trials-landscape | 2026-10-08 | 4 | 33 |
| comorbidity-and-primary-care | 2026-10-08 | 1 | 39 |
| red-flags-and-safety-concerns | 2026-10-02 | 2 | 40 |
| epidemiology-and-burden | 2026-10-01 | 3 | 36 |
| pregabalin-benzodiazepines-and-others | 2026-09-03 | 2 | 36 |
| treatment-resistant-gad | 2026-09-03 | 1 | 34 |
| screening-and-measurement | 2026-09-02 | 2 | 34 |
| special-populations | 2026-09-02 | 1 | 40 |
| digital-and-remote-delivery | 2026-09-01 | 6 | 30 |
| mechanism-and-models | 2026-06-02 | 3 | 39 |
| the-diagnostic-boundary | 2026-06-02 | 2 | 38 |
| course-relapse-and-long-term-outcome | 2026-06-01 | 2 | 25 |
| overview | 2026-06-01 | 1 | 27 |
| other-psychological-therapies | 2026-02-02 | 2 | 37 |
| patient-experience-and-advocacy | 2026-01-02 | 1 | 31 |
| ssri-and-snri-pharmacotherapy | 2025-10-02 | 0 | 30 |
| guidelines | 2025-08-01 | 0 | 43 |
| diagnosis-and-classification | 2025-07-02 | 0 | 33 |
| cognitive-behavioural-therapy | 2025-06-01 | 0 | 27 |
Recency is not quality: an old paper may be the definitive one, and a new paper may not replicate. Use this to find movement, not to rank evidence. See open questions for what remains unresolved, and the curation log for when these pages were last revised.